Experience has shown therapeutic Japanese using a real estate chemotherapy experimenters to treat cancerous tumors are different, they both promising alternative to conventional therapy or standard lung cancer, according to the American Association for Cancer Research, which published the outcome of the experiment Bdoratha "Cancer Research Clinical."The experiment was performed several therapeutic centers, and in phase II multicenter trial of 56 patients with advanced cases of lung cancer is common.The results of the experiment using a real estate S-1 and irinotecan in terms of the level of response, and survival of patients without worsening cancer, survival and overall survival, similar to or better than those reported from standard treatment with platinum-based chemotherapy regimens.Platinum toxic treatmentBecause it is a single track experience, since all participants received the same experimental treatment, without a comparison group treated with chemotherapy standard, researchers can not direct comparison between the benefits of each of my way of treatment.However, they did not say whether the side effects of an experimental treatment less severe than those usually caused by the standard treatment. It seems that patients and their physicians therapists rejecting the toxicity of chemotherapy platinum record, due to a lack of interest in the continuation of the life of patients, which reinforces the need for effective treatments with fewer toxic effects.Says study author and professor of oncology University School of Medicine Kinka Osaka in Japan Isamu Okamoto should conduct a study therapeutic "dual-track" for direct comparison between the experimental treatment and the standard treatment for prove of any benefits related to lengthening the survival of patients with the use of real estate S-1 and irinotecan.Three mechanisms workThe S-1 was approved for use in Japan and Korea, where it has shown substantial benefit in treating gastric cancer, but it is still in clinical trials in other countries, including the United States and Europe.This multi-faceted real estate and is available in capsule form, has three different mechanisms. Disintegrate in one-FU (5-FU), once its presence in the body. And الفلوروراسيل chemotherapy drug often used to treat cancers of the colon and rectum, and others.Another part of the S-1 drug-FU continues to produce a steady level and a third part is designed to counteract FU's toxic effects, such as nausea and vomiting.The irinotecan an intravenous drug, was originally developed and tested in Japan and approved in the U.S. in 1994, and is often used to treat colon cancer. And is currently being used in Japan for the treatment of lung cancer, but it is not so used in other countries.Level of response and survivalJapanese researchers believe that the combination of S-1 real estate and irinotecan offers influential solidarity. When tested as S-1 as first-line chemotherapy for advanced lung cancer, the response rate was 22%, with a median survival time of 10.2 months.In this study, enrolled in this trial patients with advanced lung cancer did not receive any treatment, in 14 treatment centers in Japan and received a median of five cycles of treatment. The response rate was 28%, and median progression-free survival of cancer about five months, and median overall survival was 15 months.See Okamoto that these results compare favorably with previous experiments dual-track chemotherapy platinum, which demonstrated response rates of 17 to 33%, a median time progression-free survival of cancer cases between three and five months, and median overall survival time of seven to 14 months.The researcher stresses that this experimental treatment promising alternative, but needs further testing through randomized trials are two-way.
.jpg)
